HK1132740A1 - Substituted oxindole derivatives and their use as vasopressin receptor ligands - Google Patents
Substituted oxindole derivatives and their use as vasopressin receptor ligandsInfo
- Publication number
- HK1132740A1 HK1132740A1 HK10100154.0A HK10100154A HK1132740A1 HK 1132740 A1 HK1132740 A1 HK 1132740A1 HK 10100154 A HK10100154 A HK 10100154A HK 1132740 A1 HK1132740 A1 HK 1132740A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor ligands
- vasopressin receptor
- oxindole derivatives
- substituted oxindole
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006062508 | 2006-12-30 | ||
DE102006062505 | 2006-12-30 | ||
DE102006062507 | 2006-12-30 | ||
DE102006062506 | 2006-12-30 | ||
PCT/EP2007/064622 WO2008080973A1 (en) | 2006-12-30 | 2007-12-28 | Substituted oxindole derivatives and their use as vasopressin receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1132740A1 true HK1132740A1 (en) | 2010-03-05 |
Family
ID=39125247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10100154.0A HK1132740A1 (en) | 2006-12-30 | 2010-01-08 | Substituted oxindole derivatives and their use as vasopressin receptor ligands |
Country Status (22)
Country | Link |
---|---|
US (4) | US8815868B2 (xx) |
EP (1) | EP2114923B1 (xx) |
JP (1) | JP5318781B2 (xx) |
KR (1) | KR101485326B1 (xx) |
AR (3) | AR064692A1 (xx) |
AU (1) | AU2007341236B2 (xx) |
BR (1) | BRPI0720866A2 (xx) |
CA (1) | CA2673584C (xx) |
CR (1) | CR10900A (xx) |
ES (1) | ES2523320T3 (xx) |
GT (1) | GT200900187A (xx) |
HK (1) | HK1132740A1 (xx) |
IL (1) | IL199265A (xx) |
MX (1) | MX2009007104A (xx) |
NZ (1) | NZ577720A (xx) |
PE (2) | PE20121442A1 (xx) |
SA (1) | SA07280709B1 (xx) |
TW (1) | TWI423804B (xx) |
UA (1) | UA96785C2 (xx) |
UY (1) | UY30846A1 (xx) |
WO (1) | WO2008080973A1 (xx) |
ZA (1) | ZA200904363B (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2009071691A2 (de) * | 2007-12-07 | 2009-06-11 | Abbott Gmbh & Co. Kg | Oxindol-derivate und ihre verwendung als medikament |
BRPI0820668A2 (pt) * | 2007-12-07 | 2017-08-22 | Abbott Gmbh & Co Kg | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina |
CA2707671C (en) * | 2007-12-07 | 2016-02-02 | Abbott Gmbh & Co. Kg | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
MX2010006202A (es) | 2007-12-07 | 2011-03-04 | Abbott Gmbh & Co Kg | Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. |
WO2010009775A1 (de) * | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
RU2487872C2 (ru) | 2007-12-27 | 2013-07-20 | Эбботт Гмбх Унд Ко.Кг | Замещенные производные оксиндола и их применение для лечения заболеваний, зависимых от вазопрессина |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
EP2440202A1 (en) * | 2009-06-10 | 2012-04-18 | Abbott GmbH & Co. KG | Use of substituted oxindole derivatives for the treatment and prophylaxis of pain |
GB201210686D0 (en) * | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
MX2015012393A (es) | 2013-03-14 | 2016-04-28 | Abbvie Deutschland | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |
AR095327A1 (es) | 2013-03-14 | 2015-10-07 | Abbvie Deutschland | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina |
GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
US9862704B2 (en) | 2013-12-20 | 2018-01-09 | AbbVie Deutschland GmbH & Co. KG | Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases |
WO2015091931A1 (en) | 2013-12-20 | 2015-06-25 | AbbVie Deutschland GmbH & Co. KG | Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases |
EP3143023B1 (en) | 2014-05-15 | 2018-04-11 | AbbVie Deutschland GmbH & Co. KG | Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases |
CN108137555B (zh) | 2015-11-06 | 2021-02-19 | 豪夫迈·罗氏有限公司 | 可用于治疗cns疾病的二氢吲哚-2-酮衍生物 |
EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns及び関連障害の治療において使用するためのインドリン−2−オン誘導体 |
CN108349944B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964896A (en) | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
CH623971B5 (de) | 1976-06-04 | 1982-01-15 | Hoechst Ag | Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller. |
JPH07502529A (ja) | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
US5914328A (en) * | 1992-10-09 | 1999-06-22 | Abbott Laboratories | Heterocyclic ether compounds useful in controlling neurotransmitter release |
US5948793A (en) * | 1992-10-09 | 1999-09-07 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release |
FR2714378B1 (fr) | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US6130217A (en) | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
FR2757157B1 (fr) * | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
DE69822668T2 (de) | 1997-12-19 | 2005-03-10 | Abbott Laboratories, Abbott Park | Heterozyklische ether- und thioether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
AU4230799A (en) | 1998-06-16 | 2000-01-05 | Targacept, Inc. | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6207863B1 (en) * | 1998-08-11 | 2001-03-27 | Rohm And Haas Company | Synthesis of haloformimine compounds |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
FR2790474B1 (fr) * | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
EP1178982B1 (en) | 1999-05-21 | 2004-06-30 | Abbott Laboratories | Heterocyclic substituted aminoazacycles useful as central nervous system agents |
US6833370B1 (en) * | 1999-05-21 | 2004-12-21 | Abbott Laboratories | Heterocycle substituted aminoazacycles useful as central nervous system agents |
JP2003501416A (ja) | 1999-06-07 | 2003-01-14 | ターガセプト,インコーポレイテッド | 医薬組成物およびその使用法 |
FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2804115B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2805536B1 (fr) | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
US6809105B2 (en) * | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
US6579880B2 (en) | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
FR2810320B1 (fr) * | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
DE10148598A1 (de) | 2001-04-19 | 2002-10-24 | Bayer Ag | Neue Arylsulfonamide als antivirale Mittel |
KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
EP1442041A1 (en) | 2001-11-08 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
US7135484B2 (en) | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
AU2003262780A1 (en) | 2002-08-20 | 2004-03-11 | The Procter And Gamble Company | Method for maufacturing liquid gel automatic dishwashing detergent compositions comprising anhydrous solvent |
ES2770035T3 (es) | 2003-04-11 | 2020-06-30 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
WO2005034952A2 (en) | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
DE102004033834A1 (de) | 2004-07-13 | 2006-02-02 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel |
NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
WO2006047392A2 (en) | 2004-10-21 | 2006-05-04 | The Trustees Of Columbia University In The City Of New York | Nicotinic-opioid synergy for analgesia |
US8378109B2 (en) | 2004-12-07 | 2013-02-19 | The Regents Of The University Of California | Labeled ALPHA4BETA2 ligands and methods therefor |
JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
CA2593044A1 (en) | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
WO2006080574A1 (ja) | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | 1,3-ジヒドロ-2h-インドール-2-オン化合物、及び芳香族複素環が縮合したピロリジン-2-オン化合物 |
US20080261999A1 (en) | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
DE102005014936A1 (de) | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
DE102005014904A1 (de) * | 2005-03-26 | 2007-02-01 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
CA2602194A1 (en) * | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |
RU2007139255A (ru) * | 2005-04-26 | 2009-06-10 | Ньюросерч А/С (DK) | Новые оксадиазольные производные и их медицинское применение |
WO2007149395A2 (en) | 2006-06-20 | 2007-12-27 | Amphora Discovery Corporation | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2008080971A1 (en) | 2006-12-30 | 2008-07-10 | Abbott Gmbh & Co. Kg | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
EP2114922B1 (en) | 2006-12-30 | 2013-04-24 | Abbott GmbH & Co. KG | Substituted oxindole derivative and its use as a vasopressin receptor modulator |
WO2008080970A1 (en) | 2006-12-30 | 2008-07-10 | Abbott Gmbh & Co. Kg | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
WO2009148452A1 (en) | 2008-06-06 | 2009-12-10 | Abbott Laboratories | Novel 1,2,4 oxadiazole compounds and methods of use thereof |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
CN101730041A (zh) | 2009-06-26 | 2010-06-09 | 中兴通讯股份有限公司 | 一种基于用户当前所在时区的策略和计费控制方法及系统 |
-
2007
- 2007-12-27 UY UY30846A patent/UY30846A1/es not_active Application Discontinuation
- 2007-12-28 EP EP07866324.2A patent/EP2114923B1/en active Active
- 2007-12-28 ES ES07866324.2T patent/ES2523320T3/es active Active
- 2007-12-28 AU AU2007341236A patent/AU2007341236B2/en not_active Ceased
- 2007-12-28 JP JP2009543480A patent/JP5318781B2/ja not_active Expired - Fee Related
- 2007-12-28 BR BRPI0720866-9A2A patent/BRPI0720866A2/pt active Search and Examination
- 2007-12-28 NZ NZ577720A patent/NZ577720A/en not_active IP Right Cessation
- 2007-12-28 TW TW096150905A patent/TWI423804B/zh not_active IP Right Cessation
- 2007-12-28 WO PCT/EP2007/064622 patent/WO2008080973A1/en active Application Filing
- 2007-12-28 US US12/521,713 patent/US8815868B2/en not_active Expired - Fee Related
- 2007-12-28 AR ARP070105964A patent/AR064692A1/es unknown
- 2007-12-28 KR KR1020097016052A patent/KR101485326B1/ko not_active IP Right Cessation
- 2007-12-28 MX MX2009007104A patent/MX2009007104A/es active IP Right Grant
- 2007-12-28 UA UAA200908025A patent/UA96785C2/uk unknown
- 2007-12-28 CA CA2673584A patent/CA2673584C/en not_active Expired - Fee Related
- 2007-12-29 SA SA07280709A patent/SA07280709B1/ar unknown
-
2008
- 2008-01-02 PE PE2012000798A patent/PE20121442A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2008000063A patent/PE20081557A1/es not_active Application Discontinuation
-
2009
- 2009-06-09 IL IL199265A patent/IL199265A/en not_active IP Right Cessation
- 2009-06-22 ZA ZA2009/04363A patent/ZA200904363B/en unknown
- 2009-06-29 GT GT200900187A patent/GT200900187A/es unknown
- 2009-06-30 CR CR10900A patent/CR10900A/es unknown
-
2010
- 2010-01-08 HK HK10100154.0A patent/HK1132740A1/xx not_active IP Right Cessation
- 2010-07-15 AR ARP100102572A patent/AR077415A2/es unknown
- 2010-07-15 AR ARP100102571A patent/AR077478A2/es unknown
-
2012
- 2012-08-21 US US13/590,261 patent/US8859557B2/en not_active Expired - Fee Related
-
2014
- 2014-09-09 US US14/481,847 patent/US20140378471A1/en not_active Abandoned
-
2015
- 2015-06-16 US US14/740,598 patent/US20150352110A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1132740A1 (en) | Substituted oxindole derivatives and their use as vasopressin receptor ligands | |
HK1132741A1 (en) | Substituted oxindole derivative and its use as a vasopressin receptor ligand | |
IL188039A0 (en) | Oxindole derivatives | |
IL196267A0 (en) | Indole derivatives and pharmaceutical compositions containing the same | |
EP2049520A4 (en) | indole compounds | |
IL201195A0 (en) | 4-aza indole derivatives and their use as fungicides | |
ZA200806392B (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists | |
EP2035376A4 (en) | INDOLINAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | |
IL190587A0 (en) | Substituted benzofused derivatives and their use as vanilliod receptor ligands | |
EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
IL195492A0 (en) | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands | |
EP2079466A4 (en) | SUBSTITUTED INDOLE COMPOUNDS | |
HK1163077A1 (en) | Benzazepine derivatives useful as vasopressin antagonists | |
IL194391A0 (en) | 5-amido-2-carboxamide indoles | |
IL197232A0 (en) | Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists | |
IL192270A0 (en) | Substituted oxadiazole derivatives and their use as opioid receptor ligands | |
IL199430A0 (en) | Crth2 antagonists | |
IL198334A0 (en) | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists | |
EP2121703A4 (en) | THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS | |
ZA200905265B (en) | Indole derivatives | |
GB0524427D0 (en) | Use of receptor ligands in threapy | |
IL198633A0 (en) | Indoles | |
HK1132994A1 (en) | Mtki quinazoline derivatives mtki | |
ZA200900843B (en) | Indole compounds | |
ZA200802339B (en) | Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181228 |